Related Experiment Videos
Assessment of risk in metastatic testis carcinoma: impact on treatment
D F Bajorin1, N L Geller, G J Bosl
1Department of Medicine, Memorial Sloan-Kettering Cancer, New York, N.Y.
Abstract:
The majority of patients have 'good risk' nonseminomatous germ cell tumors, that is, they are likely to obtain an initial complete response to chemotherapy. Trials in these patients attempt to reduce the toxicity of chemotherapy. The minority of patients have refractory disease ('poor risk' nonseminomatous germ cell tumors) and the primary objective in this population is to improve the proportion of complete response. Chemotherapy trials for the poor risk group are generally associated with greater toxicity. Clinical factors reported to impact on the prognosis of nonseminomatous germ cell tumor patients include the pretreatment level of serum tumor markers (AFP, HCG, LDH), extern or bulk of disease, the pathology and the site of the primary lesion. No consensus currently exists on which factors are most important in determining prognosis and how they should be used to allocate patients to good and poor risk nonseminomatous germ cell tumors trials. The data support the concept that biologic markers and extent or bulk of disease together are more predictive of response and survival than either one alone and their combined use results in a smaller percent of the germ cell tumor population allocated to poor risk trials. This minimizes exposure of good risk patients to toxic regimens and still maintains a high response rate in the good risk population. The current eligibility criteria for good and poor risk trials in use directly affects the reported response proportion and survival. In view of these differences, good and poor risk trials should be randomized against a comparative control population and nonrandomized trials comparing treatment results with those of other studies or historical controls should be viewed with extreme caution.
Insights
Combining biologic markers and disease extent improves nonseminomatous germ cell tumor risk stratification. This approach optimizes chemotherapy trials by minimizing exposure of good-risk patients to toxic regimens while maintaining high response rates.
Area of Science:
- Oncology
- Medical Research
Background:
- Nonseminomatous germ cell tumors (NSGCT) present varying prognoses.
- Good-risk NSGCT patients typically respond well to chemotherapy, with trials focusing on reducing toxicity.
- Poor-risk NSGCT patients have refractory disease, necessitating improved complete response rates, often with higher toxicity regimens.
Purpose of the Study:
- To evaluate the predictive value of clinical factors for NSGCT prognosis.
- To determine optimal criteria for allocating patients to good-risk and poor-risk NSGCT clinical trials.
- To refine risk stratification for NSGCT treatment strategies.
Main Methods:
- Analysis of clinical factors influencing NSGCT prognosis, including serum tumor markers (AFP, HCG, LDH), disease extent, pathology, and primary lesion site.
- Assessment of the combined predictive power of biologic markers and disease extent for treatment response and survival.
- Evaluation of current eligibility criteria for NSGCT risk-stratified trials.
Main Results:
- No consensus exists on the most critical prognostic factors for NSGCT.
- Biologic markers and disease extent, when used together, are more predictive of response and survival than either factor alone.
- Combined risk stratification allocates fewer patients to poor-risk trials, protecting good-risk patients from excessive toxicity.
Conclusions:
- Combined assessment of biologic markers and disease extent improves NSGCT risk stratification.
- Optimized risk stratification enhances the safety and efficacy of chemotherapy trials for NSGCT.
- Randomized trials comparing treatment arms are crucial for reliable NSGCT outcome assessment.